{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/pfizer-pfe/",
 "dataUrl": "https://clearank.com/stock/pfizer-pfe/data.json",
 "title": "Pfizer (PFE) Stock Forecast & Price Target (2026)",
 "description": "Pfizer Inc. (PFE) stock: Healthcare, Drug Manufacturers - General. $163.4B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Pfizer Inc. (PFE)",
 "published": "2026-06-07T09:07:34+00:00",
 "modified": "2026-09-27T03:36:43.124+00:00",
 "generated": "2026-09-27T14:17:54.740Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "PFE",
  "name": "Pfizer Inc.",
  "type": "Common Stock",
  "exchange": "NYSE",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Drug Manufacturers - General",
  "country": "United States",
  "website": "https://www.pfizer.com"
 },
 "quote": {
  "price": 28.67,
  "previousClose": 28.41,
  "change": 0.26,
  "changePercent": 0.92,
  "open": 28.45,
  "high": 28.69,
  "low": 28.17,
  "volume": 27755200,
  "averageVolume": 35142240,
  "marketCap": 163409641796,
  "fiftyTwoWeekHigh": 29.21,
  "fiftyTwoWeekLow": 23.58,
  "marketOpen": false,
  "asOf": "2026-09-27T03:36:43.000Z"
 },
 "statistics": {
  "pe": 37.723686,
  "eps": 0.76,
  "dividendYield": 0.05996165354795112,
  "beta": 0.299,
  "priceToSales": 2.5654616,
  "priceToBook": 1.9179823,
  "revenueTtm": 63695998976,
  "grossMargin": 0.7278169482506319,
  "returnOnEquity": 0.05014
 },
 "technicals": {
  "rsi": 54.7,
  "macd": 0.28,
  "sma50": 26.98,
  "sma200": 26.34,
  "rsiSignal": "Neutral",
  "trend": "Bullish",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Bullish"
 },
 "analysis": {
  "rating": "Hold",
  "score": 58,
  "consensus": "Hold",
  "fairValue": 28.67,
  "analystTarget": 28,
  "analystCount": 28,
  "wallStreetConsensus": "Hold",
  "generatedAt": "2026-09-27T03:36:43.000Z",
  "priceAtAnalysis": 28.67,
  "volatility": {
   "daily": 1.19,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Neutral",
  "conservativeEntry": 28.38,
  "aggressiveEntry": 28.67,
  "stopLoss": 27.53,
  "stopLossPercent": 3,
  "targets": [
   29.23,
   29.8,
   30.65
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 21.56,
    "base": 29.39,
    "upside90th": 40.06
   },
   {
    "year": 2028,
    "downside10th": 19.44,
    "base": 30.13,
    "upside90th": 46.69
   },
   {
    "year": 2029,
    "downside10th": 18.06,
    "base": 30.88,
    "upside90th": 52.81
   },
   {
    "year": 2030,
    "downside10th": 17.04,
    "base": 31.66,
    "upside90th": 58.82
   },
   {
    "year": 2031,
    "downside10th": 16.24,
    "base": 32.46,
    "upside90th": 64.88
   },
   {
    "year": 2032,
    "downside10th": 15.58,
    "base": 33.27,
    "upside90th": 71.05
   },
   {
    "year": 2033,
    "downside10th": 15.03,
    "base": 34.11,
    "upside90th": 77.4
   },
   {
    "year": 2034,
    "downside10th": 14.56,
    "base": 34.96,
    "upside90th": 83.96
   },
   {
    "year": 2035,
    "downside10th": 14.15,
    "base": 35.84,
    "upside90th": 90.77
   },
   {
    "year": 2036,
    "downside10th": 13.8,
    "base": 36.74,
    "upside90th": 97.84
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "PFE Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$28.45",
    "Day Range": "$28.17 to $28.69",
    "Prev Close": "$28.41",
    "Volume": "27.76M",
    "52-Week Range": "$23.58 to $29.21",
    "Market Cap": "$163.41B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Valuation is broadly in line with sector peers (18% difference), suggesting fair market pricing relative to industry standards."
   ]
  },
  {
   "id": "financials",
   "title": "PFE Financial Performance"
  },
  {
   "id": "analysis",
   "title": "PFE Analysis",
   "text": [
    "Pfizer Inc. (PFE) exhibits neutral momentum with an RSI of 54.7, trading above its 50-day and 200-day moving averages ($26.98 and $26.34), indicating that these moving averages are acting as support. The MACD is slightly positive at 0.28, suggesting a lack of strong directional conviction. The stochastic indicator is in overbought territory at 88.75, which could signal a potential short-term pullback. Volume has been below its average recently, with the latest volume at 27.76 million compared to an average of 35.14 million, a decrease of 21%. The current price of $28.67 is above its 50-day and 200-day moving averages ($26.98 and $26.34). The CCI at 188.51 suggests strong positive momentum, though this is tempered by the neutral RSI and overbought stochastic reading.",
    "Insiders, including CEO an insider, have made net purchases totaling $3 million, indicating confidence in the company's future prospects.",
    "Current estimates show a decline in revenue and EPS for the upcoming quarters and full year, alongside negative long-term growth projections.",
    "The median analyst price target of $28.00 is slightly below the current stock price of $28.67, indicating a lack of significant upside potential.",
    "The stochastic indicator is at 88.75, suggesting the stock may be overbought in the short term and could experience a pullback.",
    "Pfizer Inc. (PFE) faces a challenging outlook, with projected revenue and EPS declines in the near term and negative growth estimates for the next five years. The current trading price of $28.67 is slightly above the median analyst price target of $28.00, suggesting limited upside potential. The company's valuation metrics, particularly its P/E ratio, appear rich relative to its growth prospects and current profitability. Key factors that could influence the stock's trajectory include the success of its drug pipeline and the market's reaction to upcoming earnings reports. While insider buying provides some support, the overall analyst sentiment leans towards 'Hold', reflecting concerns about future growth and current valuation. Investors should monitor the company's ability to reverse its revenue decline and achieve positive growth in the coming years."
   ],
   "lists": {
    "ProTips": [
     "Monitor Pfizer's upcoming earnings reports closely for any signs of revenue stabilization or growth acceleration, as current projections indicate a decline.",
     "Given the neutral RSI and overbought stochastic reading, consider potential short-term volatility or a minor pullback in PFE's stock price.",
     "As an MLP, Pfizer Inc. issues Schedule K-1 tax forms instead of standard 1099-DIV forms, which may create complex tax obligations-especially if held in a retirement account (IRA/401k). Consult a tax advisor."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Insider Buying Signals Moderate Accumulation",
     "text": "Insiders, including CEO an insider, have made net purchases totaling $3 million, indicating confidence in the company's future prospects.",
     "source": "Insider Trading Data"
    },
    {
     "type": "Bearish",
     "title": "Projected Revenue and EPS Decline",
     "text": "Current estimates show a decline in revenue and EPS for the upcoming quarters and full year, alongside negative long-term growth projections.",
     "source": "Analyst Estimates"
    },
    {
     "type": "Neutral",
     "title": "Median Analyst Price Target Suggests Limited Upside",
     "text": "The median analyst price target of $28.00 is slightly below the current stock price of $28.67, indicating a lack of significant upside potential.",
     "source": "Wall Street Summary"
    },
    {
     "type": "Neutral",
     "title": "Overbought Stochastic Indicator",
     "text": "The stochastic indicator is at 88.75, suggesting the stock may be overbought in the short term and could experience a pullback.",
     "source": "Technical Analysis"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Pfizer Inc. (PFE) trades at a P/E ratio of 37.72, which is higher than the healthcare sector median of 31.9, suggesting a premium valuation relative to its earnings. Its price-to-sales ratio of 2.57 is below the sector average of 3.7, indicating that the market values its revenue less than its peers. The company's return on equity is 5.01%, and its profit margin is 6.80%, both of which are below the sector medians of 6.9% and 8.1% respectively. Despite lower profitability metrics compared to sector averages, Pfizer maintains a strong operating margin of 27.88%. Its debt-to-equity ratio stands at 0.74, which is slightly above the sector median of 0.74, indicating a moderate level of leverage. The company's revenue growth is projected to be negative for the current and next quarters, and the consensus estimate for the next five years is a compound annual growth rate of -4.4%, signaling potential challenges in expanding its top line.",
    "Pfizer Inc. (PFE) is expected to report earnings per share of $0.75885 for the current quarter ending September 30, 2026, a decrease from $0.87 in the year-ago period, with an estimated sales growth of -4.00%. For the full year 2026, EPS is projected at $2.97497, down from $3.22 last year, and revenue is expected to decline by 1.00%. The company's growth estimates indicate a challenging near-term outlook, with projected EPS declines in the current and next quarters, and negative revenue growth expected for the next year.",
    "Pfizer Inc. (PFE) faces risks related to its valuation, trading at a higher P/E ratio than the healthcare sector median, despite projected revenue and EPS declines. The company's forward growth estimates are negative, particularly for the next five years, suggesting potential long-term challenges in expanding its business. Also, the median analyst price target of $28.00 is slightly below the current trading price of $28.67, indicating limited upside potential according to Wall Street."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "163.41B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "37.72"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "0.7600"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "6.00%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "29.21"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "23.58"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bullish RSI Neutral SMA Cross Bullish Price vs SMA Bullish MACD Bullish Golden Cross in effect with the 50-day SMA ($26.98) above the 200-day SMA ($26.34), price action is firmly bullish above key moving averages."
   ],
   "facts": {
    "RSI": "Neutral",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bullish",
    "MACD": "Bullish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "54.70"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "0.28"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "26.98"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "26.34"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.26",
    "Correlation with Nasdaq 100 (QQQ)": "+0.14",
    "Correlation with Bitcoin (BTC)": "+0.23",
    "Correlation with Gold (XAU)": "+0.07"
   }
  },
  {
   "id": "trade-plans",
   "title": "PFE Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Enter now if confident",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (54.7) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$29.23",
    "TARGET 2": "$29.80",
    "TARGET 3": "$30.65",
    "STOP LOSS": "$27.53"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "-3.65%",
    "Average Feb return": "-2.73%",
    "Average Mar return": "+1.67%",
    "Average Apr return": "+0.02%",
    "Average May return": "+0.84%",
    "Average Jun return": "-1.06%",
    "Average Jul return": "+1.99%",
    "Average Aug return": "+0.31%",
    "Average Sep return": "-0.75%",
    "Average Oct return": "-1.88%",
    "Average Nov return": "+4.90%",
    "Average Dec return": "+0.27%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "1.19%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in PFE in September 2016 would be worth about $8,932 today, compared with about $35,782 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in PFE today could grow to about $12,815 by 2036 in the base case, with a bull case near $34,127 and a bear case around $4,812. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "PFE Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $31.66 for PFE by 2030 in the base case, from $28.67 today (1.1x over 4 years). The downside path ends near $17.04. These are outcomes of a Monte Carlo simulation run on PFE's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using PFE's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "PFE simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$21.56",
        "$29.39",
        "$40.06"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$19.44",
        "$30.13",
        "$46.69"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$18.06",
        "$30.88",
        "$52.81"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$17.04",
        "$31.66",
        "$58.82"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$16.24",
        "$32.46",
        "$64.88"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$15.58",
        "$33.27",
        "$71.05"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$15.03",
        "$34.11",
        "$77.40"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$14.56",
        "$34.96",
        "$83.96"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$14.15",
        "$35.84",
        "$90.77"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$13.80",
        "$36.74",
        "$97.84"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "AMGN Amgen Inc. NASDAQ $414.61 +2.11%",
     "url": "https://clearank.com/stock/amgen-amgn/"
    },
    {
     "text": "HIMS Hims & Hers Health, Inc. NYSE $29.42 +0.48%",
     "url": "https://clearank.com/stock/hims-hers-health-hims/"
    },
    {
     "text": "NEOG Neogen Corp. NASDAQ $13.76 +0.73%",
     "url": "https://clearank.com/stock/neogen-neog/"
    },
    {
     "text": "NVO Novo Nordisk A/S Sponsored NYSE $38.80 +0.47%",
     "url": "https://clearank.com/stock/novo-nordisk-nvo/"
    },
    {
     "text": "LEGN Legend Biotech Corporation NASDAQ $19.11 +0.26%",
     "url": "https://clearank.com/stock/legend-biotech-legn/"
    },
    {
     "text": "MOH Molina Healthcare Inc. NYSE $190.86 -1.27%",
     "url": "https://clearank.com/stock/moh-stock-analysis/"
    },
    {
     "text": "VKTX Viking Therapeutics, Inc. NASDAQ $35.56 -3.24%",
     "url": "https://clearank.com/stock/viking-therapeutics-vktx/"
    },
    {
     "text": "CI The Cigna Group NYSE $272.01 +2.45%",
     "url": "https://clearank.com/stock/cigna-group-ci/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Compare PFE",
   "links": [
    {
     "text": "PFE vs MRK Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/pfe-vs-mrk/"
    },
    {
     "text": "QQQ vs QQQM Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/qqq-vs-qqqm/"
    },
    {
     "text": "XLF vs XLK Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/xlf-vs-xlk/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "PFE Insider Trading Analysis",
   "facts": {
    "Bought": "$3.0M",
    "Sold": "$134.7K",
    "Insiders": "9",
    "Avg Transaction": "$619.0K"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in PFE",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Mar 4, 2019",
       "cells": [
        "READ IAN C Officer and Director",
        "Sell",
        "530.1K",
        "$22.9M"
       ]
      },
      {
       "label": "Jul 16, 2018",
       "cells": [
        "READ IAN C Chief Executive Officer",
        "Sell",
        "486.8K",
        "$18.2M"
       ]
      },
      {
       "label": "Nov 11, 2021",
       "cells": [
        "YOUNG JOHN D Officer",
        "Sell",
        "150.0K",
        "$7.5M"
       ]
      },
      {
       "label": "Jul 2, 2019",
       "cells": [
        "D AMELIO FRANK A Officer",
        "Sell",
        "153.2K",
        "$6.8M"
       ]
      },
      {
       "label": "Mar 4, 2019",
       "cells": [
        "DOLSTEN MIKAEL G M.D., PH.D. Officer",
        "Sell",
        "149.6K",
        "$6.5M"
       ]
      },
      {
       "label": "Aug 1, 2018",
       "cells": [
        "D AMELIO FRANK A Officer",
        "Sell",
        "150.5K",
        "$6.0M"
       ]
      },
      {
       "label": "Nov 9, 2020",
       "cells": [
        "BOURLA ALBERT Chief Executive Officer",
        "Sell",
        "132.5K",
        "$5.6M"
       ]
      },
      {
       "label": "May 1, 2018",
       "cells": [
        "READ IAN C Chief Executive Officer",
        "Sell",
        "132.3K",
        "$4.8M"
       ]
      },
      {
       "label": "May 18, 2020",
       "cells": [
        "DOLSTEN MIKAEL G M.D., PH.D. Officer",
        "Sell",
        "95.4K",
        "$3.6M"
       ]
      },
      {
       "label": "Nov 11, 2021",
       "cells": [
        "DOLSTEN MIKAEL G M.D., PH.D. Officer",
        "Sell",
        "59.7K",
        "$3.0M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Pfizer+Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is Pfizer Inc.'s current stock price and consensus rating?",
   "answer": "Pfizer Inc. (PFE) is currently trading at $28.67. The consensus rating among Wall Street analysts is 'Hold', with a consensus score of 58 out of 100."
  },
  {
   "question": "What is the median analyst price target for PFE stock?",
   "answer": "The median analyst price target for Pfizer Inc. (PFE) is $28.00, which suggests a slight downside of -2.3% from its current trading price of $28.67."
  },
  {
   "question": "How does Pfizer's valuation compare to the healthcare sector?",
   "answer": "Pfizer Inc. (PFE) trades at a P/E ratio of 37.72, which is higher than the healthcare sector median of 31.9. However, its price-to-sales ratio of 2.57 is below the sector average of 3.7."
  },
  {
   "question": "What is the recent insider trading activity for Pfizer Inc.?",
   "answer": "Insider activity for Pfizer Inc. (PFE) indicates a 'Moderate Buy Signal', with insiders being net buyers. Total purchases amount to $3 million, primarily from CEO Albert Bourla, against $134.7 thousand in sales in recent filings."
  },
  {
   "question": "What are the projected earnings and revenue growth estimates for Pfizer?",
   "answer": "For the current year, Pfizer Inc. (PFE) is projected to have EPS of $2.97 and revenue of $62.2 billion, representing a year-over-year decline. Growth estimates are negative for the next five years at -4.4% annually."
  },
  {
   "question": "Is Pfizer Inc. stock technically overbought or oversold?",
   "answer": "Pfizer Inc. (PFE) shows neutral momentum with an RSI at 54.7. While the stochastic indicator is in overbought territory at 88.75, suggesting a potential short-term pullback, the stock is trading above its key moving averages, indicating support."
  },
  {
   "question": "What is Pfizer's long-range projection for 2030?",
   "answer": "Based on Monte Carlo simulations, Pfizer Inc. (PFE) has a base case projection of $31.66 for 2030, with a downside scenario of $17.04 and an upside scenario of $58.82. These are statistical outcomes, not guarantees."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "AMGN",
    "name": "Amgen Inc. NASDAQ",
    "price": "$414.61",
    "change": "+2.11%",
    "url": "https://clearank.com/stock/amgen-amgn/"
   },
   {
    "ticker": "HIMS",
    "name": "Hims & Hers Health, Inc. NYSE",
    "price": "$29.42",
    "change": "+0.48%",
    "url": "https://clearank.com/stock/hims-hers-health-hims/"
   },
   {
    "ticker": "NEOG",
    "name": "Neogen Corp. NASDAQ",
    "price": "$13.76",
    "change": "+0.73%",
    "url": "https://clearank.com/stock/neogen-neog/"
   },
   {
    "ticker": "NVO",
    "name": "Novo Nordisk A/S Sponsored NYSE",
    "price": "$38.80",
    "change": "+0.47%",
    "url": "https://clearank.com/stock/novo-nordisk-nvo/"
   },
   {
    "ticker": "LEGN",
    "name": "Legend Biotech Corporation NASDAQ",
    "price": "$19.11",
    "change": "+0.26%",
    "url": "https://clearank.com/stock/legend-biotech-legn/"
   },
   {
    "ticker": "MOH",
    "name": "Molina Healthcare Inc. NYSE",
    "price": "$190.86",
    "change": "-1.27%",
    "url": "https://clearank.com/stock/moh-stock-analysis/"
   },
   {
    "ticker": "VKTX",
    "name": "Viking Therapeutics, Inc. NASDAQ",
    "price": "$35.56",
    "change": "-3.24%",
    "url": "https://clearank.com/stock/viking-therapeutics-vktx/"
   },
   {
    "ticker": "CI",
    "name": "The Cigna Group NYSE",
    "price": "$272.01",
    "change": "+2.45%",
    "url": "https://clearank.com/stock/cigna-group-ci/"
   }
  ],
  "comparisons": [
   {
    "ticker": "PFE vs MRK Comparison",
    "name": "",
    "url": "https://clearank.com/compare/pfe-vs-mrk/"
   },
   {
    "ticker": "QQQ vs QQQM Comparison",
    "name": "",
    "url": "https://clearank.com/compare/qqq-vs-qqqm/"
   },
   {
    "ticker": "XLF vs XLK Comparison",
    "name": "",
    "url": "https://clearank.com/compare/xlf-vs-xlk/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "FIS",
    "text": "Fidelity National Information Services, Inc.",
    "url": "https://clearank.com/stock/fis-stock-analysis/"
   },
   {
    "ticker": "EXC",
    "text": "Exelon Corp.",
    "url": "https://clearank.com/stock/exc-stock-analysis/"
   },
   {
    "ticker": "GWW",
    "text": "W.W. Grainger Inc.",
    "url": "https://clearank.com/stock/gww-stock-analysis/"
   },
   {
    "ticker": "CDE",
    "text": "Coeur Mining Inc.",
    "url": "https://clearank.com/stock/cde-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "BLNE",
    "text": "↓ 7.40%",
    "url": "https://clearank.com/stock/blne-beeline-holdings/"
   },
   {
    "ticker": "GRT/USD",
    "text": "↑ 20.82%",
    "url": "https://clearank.com/crypto/the-graph-grt/"
   },
   {
    "ticker": "SEI/USD",
    "text": "↑ 19.29%",
    "url": "https://clearank.com/crypto/sei-sei/"
   },
   {
    "ticker": "WLD/USD",
    "text": "↑ 17.41%",
    "url": "https://clearank.com/crypto/worldcoin-wld/"
   },
   {
    "ticker": "ETHFI/USD",
    "text": "↓ 13.68%",
    "url": "https://clearank.com/crypto/ethfi-usd-crypto-analysis/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "GILD",
    "text": "Gilead Sciences",
    "url": "https://clearank.com/stock/gilead-sciences-gild/"
   },
   {
    "ticker": "JNJ",
    "text": "Johnson & Johnson",
    "url": "https://clearank.com/stock/johnson-johnson-jnj/"
   },
   {
    "ticker": "LLY",
    "text": "Eli Lilly",
    "url": "https://clearank.com/stock/eli-lilly-lly/"
   },
   {
    "ticker": "MRK",
    "text": "Merck",
    "url": "https://clearank.com/stock/merck-mrk/"
   },
   {
    "ticker": "NVO",
    "text": "Novo Nordisk",
    "url": "https://clearank.com/stock/novo-nordisk-nvo/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/06/pfizer-pfe.png",
     "url": "https://clearank.com/wp-content/uploads/2026/06/pfizer-pfe.png",
     "width": "1280",
     "height": "720",
     "caption": "Pfizer Inc. (PFE) stock price analysis chart for June 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/pfizer-pfe/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/pfizer-pfe/",
        "name": "Pfizer (PFE) Stock Price Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/pfizer-pfe/#webpage",
     "url": "https://clearank.com/stock/pfizer-pfe/",
     "name": "Pfizer (PFE) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-06-07T09:07:34+00:00",
     "dateModified": "2026-09-27T03:36:43+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/pfizer-pfe.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/pfizer-pfe/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/pfizer-pfe/#richSnippet",
     "headline": "Pfizer (PFE) Stock Forecast & Price Target (2026)",
     "name": "Pfizer (PFE) Stock Forecast & Price Target (2026)",
     "description": "Pfizer Inc. (PFE) stock: Healthcare, Drug Manufacturers - General. $163.4B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "datePublished": "2026-06-07T09:07:34+00:00",
     "dateModified": "2026-09-27T03:36:43+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "Pfizer Inc.",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "PFE"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NYSE"
       }
      ],
      "description": "Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines for people worldwide. Its current portfolio spans oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and hospital-based care, supported by a br",
      "tickerSymbol": "PFE",
      "sameAs": "https://www.pfizer.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/pfizer-pfe/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/pfizer-pfe.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/pfizer-pfe/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is Pfizer Inc.'s current stock price and consensus rating?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Pfizer Inc. (PFE) is currently trading at $28.67. The consensus rating among Wall Street analysts is 'Hold', with a consensus score of 58 out of 100."
     }
    },
    {
     "@type": "Question",
     "name": "What is the median analyst price target for PFE stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The median analyst price target for Pfizer Inc. (PFE) is $28.00, which suggests a slight downside of -2.3% from its current trading price of $28.67."
     }
    },
    {
     "@type": "Question",
     "name": "How does Pfizer's valuation compare to the healthcare sector?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Pfizer Inc. (PFE) trades at a P/E ratio of 37.72, which is higher than the healthcare sector median of 31.9. However, its price-to-sales ratio of 2.57 is below the sector average of 3.7."
     }
    },
    {
     "@type": "Question",
     "name": "What is the recent insider trading activity for Pfizer Inc.?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Insider activity for Pfizer Inc. (PFE) indicates a 'Moderate Buy Signal', with insiders being net buyers. Total purchases amount to $3 million, primarily from CEO Albert Bourla, against $134.7 thousand in sales across 13 transactions."
     }
    },
    {
     "@type": "Question",
     "name": "What are the projected earnings and revenue growth estimates for Pfizer?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "For the current year, Pfizer Inc. (PFE) is projected to have EPS of $2.97497 and revenue of $62.2 billion, representing a year-over-year decline. Growth estimates are negative for the next five years at -4.4% annually."
     }
    },
    {
     "@type": "Question",
     "name": "Is Pfizer Inc. stock technically overbought or oversold?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Pfizer Inc. (PFE) shows neutral momentum with an RSI of 54.7. While the stochastic indicator is in overbought territory at 88.75, suggesting a potential short-term pullback, the stock is trading above its key moving averages, indicating support."
     }
    },
    {
     "@type": "Question",
     "name": "What is Pfizer's long-range projection for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, Pfizer Inc. (PFE) has a base case projection of $31.66 for 2030, with a downside scenario of $17.04 and an upside scenario of $58.82. These are statistical outcomes, not guarantees."
     }
    }
   ]
  }
 ]
}